H
RXRX icon

HoyleCohen’s Recursion Pharmaceuticals RXRX Stock Holding History

HoyleCohen’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$341K Buy
+45,522
New +$397K 0.03% 215

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HoyleCohen's RXRX Position: Q2 2024 in Review

HoyleCohen opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2024: 45,522 shares worth $341K. The stake represents 0.03% of the portfolio and ranks #215 among its holdings.

270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

  • HoyleCohen held 45,522 shares of Recursion Pharmaceuticals worth $341K as of Q2 2024.
  • Recursion Pharmaceuticals was a new HoyleCohen position in Q2 2024.
  • Recursion Pharmaceuticals made up 0.03% of HoyleCohen's portfolio in Q2 2024, its #215 holding.
  • 270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on HoyleCohen's 13F filing for Q2 2024, filed 19 Jul 2024.